EPILEPSY, CHILDHOOD ABSENCE, SUSCEPTIBILITY TO, 2: genes and variants
Explore variant evidence for EPILEPSY, CHILDHOOD ABSENCE, SUSCEPTIBILITY TO, 2 across 3 analyzed proteins (GABRB3, GABRG2, GABRA1). Linked ClinVar records include 80 pathogenic or likely pathogenic variants, 458 variants of uncertain significance and 74 with conflicting classifications.
Coverage includes proteins already analyzed in CATVariant, not every gene involved in this condition. Database links are associations, not an assessment of clinical gene–disease validity. Computable evidence prioritizes variants for expert review and does not reclassify them. Source labels are pooled across this disease family.
Data updated 2026-11-05. Automated aggregation, not a clinical review date.
Download variant evidence (CSV)
Genes linked to EPILEPSY, CHILDHOOD ABSENCE, SUSCEPTIBILITY TO, 2
GABRB3: Gamma-aminobutyric acid receptor subunit beta-3
It contributes to inhibitory GABA-A receptor currents in the brain and is particularly important during neurodevelopment. Pathogenic variants can cause developmental and epileptic encephalopathy, while altered dosage within chromosome 15q11-q13 contributes to neurodevelopmental disorders.
33 ClinVar pathogenic / likely pathogenic and 180 uncertain variants in GABRB3 have source records linked to EPILEPSY, CHILDHOOD ABSENCE, SUSCEPTIBILITY TO, 2. Association strength is not clinical gene validity.
GABRG2: Gamma-aminobutyric acid receptor subunit gamma-2
The gene product supplies the gamma-2 subunit of synaptic GABA-A receptors, which are pentameric chloride channels activated by the inhibitory neurotransmitter GABA. The subunit helps receptor assembly and localization at neuronal membranes, and GABRG2 variants are associated with several epilepsy syndromes.
28 ClinVar pathogenic / likely pathogenic and 201 uncertain variants in GABRG2 have source records linked to EPILEPSY, CHILDHOOD ABSENCE, SUSCEPTIBILITY TO, 2. Association strength is not clinical gene validity.
GABRA1: Gamma-aminobutyric acid receptor subunit alpha-1
The gene product supplies the alpha-1 subunit of a pentameric GABA-A receptor, a ligand-gated chloride channel in the brain. GABA binding allows chloride influx that dampens neuronal activity, making this receptor important for inhibition and seizure biology.
19 ClinVar pathogenic / likely pathogenic and 151 uncertain variants in GABRA1 have source records linked to EPILEPSY, CHILDHOOD ABSENCE, SUSCEPTIBILITY TO, 2. Association strength is not clinical gene validity.
Where EPILEPSY, CHILDHOOD ABSENCE, SUSCEPTIBILITY TO, 2 variants cluster
- GABRG2 Extracellular (positions 323–334): 5 of 23 ClinVar pathogenic / likely pathogenic variants, 8.6× more than its size predicts (a length-based count, not a validated hotspot).
- GABRA1 Transmembrane (positions 280–301): 5 of 19 ClinVar pathogenic / likely pathogenic variants, 5.5× more than its size predicts (a length-based count, not a validated hotspot).
- GABRG2 Transmembrane (positions 303–322): 5 of 23 ClinVar pathogenic / likely pathogenic variants, 5.2× more than its size predicts (a length-based count, not a validated hotspot).
ClinVar pathogenic and likely pathogenic variants linked to EPILEPSY, CHILDHOOD ABSENCE, SUSCEPTIBILITY TO, 2
| Variant | Position | Protein part | Clinical label |
|---|---|---|---|
| GABRG2 R82Q | 82 | Extracellular | Pathogenic / likely pathogenic (★★) |
| GABRG2 R82W | 82 | Extracellular | Pathogenic / likely pathogenic (★★) |
| GABRB3 D49N | 49 | Extracellular | Pathogenic / likely pathogenic (★★) |
| GABRB3 P253T | 253 | Transmembrane | Pathogenic / likely pathogenic (★★) |
| GABRB3 S254F | 254 | Transmembrane | Pathogenic / likely pathogenic (★★) |
| GABRG2 R323Q | 323 | Extracellular | Pathogenic / likely pathogenic (★★) |
| GABRG2 Y331C | 331 | Extracellular | Pathogenic / likely pathogenic (★★) |
| GABRA1 T289A | 289 | Transmembrane | Pathogenic / likely pathogenic (★★) |
| GABRB3 L52V | 52 | Extracellular | Pathogenic / likely pathogenic (★★) |
| GABRB3 R232Q | 232 | Extracellular | Pathogenic / likely pathogenic (★★) |
| GABRB3 P301L | 301 | Extracellular | Pathogenic / likely pathogenic (★★) |
| GABRB3 Y302C | 302 | Extracellular | Pathogenic / likely pathogenic (★★) |
| GABRB3 K304R | 304 | Extracellular | Pathogenic / likely pathogenic (★★) |
| GABRG2 T310I | 310 | Transmembrane | Pathogenic / likely pathogenic (★★) |
| GABRG2 S325L | 325 | Extracellular | Pathogenic / likely pathogenic (★★) |
| GABRA1 R147Q | 147 | Extracellular | Pathogenic / likely pathogenic (★★) |
| GABRG2 G257R | 257 | Extracellular | Pathogenic / likely pathogenic (★★) |
| GABRA1 R214C | 214 | Extracellular | Pathogenic / likely pathogenic (★★) |
| GABRA1 T295I | 295 | Transmembrane | Pathogenic / likely pathogenic (★★) |
| GABRB3 Y99C | 99 | Extracellular | Pathogenic / likely pathogenic (★★) |
| GABRB3 D120N | 120 | Extracellular | Pathogenic / likely pathogenic (★★) |
| GABRB3 L124F | 124 | Extracellular | Pathogenic / likely pathogenic (★★) |
| GABRB3 Y184C | 184 | Extracellular | Pathogenic / likely pathogenic (★★) |
| GABRB3 T185I | 185 | Extracellular | Pathogenic / likely pathogenic (★★) |
| GABRB3 I280F | 280 | Transmembrane | Pathogenic / likely pathogenic (★★) |
| GABRB3 T288I | 288 | Transmembrane | Pathogenic / likely pathogenic (★★) |
| GABRG2 T90M | 90 | Extracellular | Pathogenic / likely pathogenic (★★) |
| GABRG2 N167K | 167 | Extracellular | Pathogenic / likely pathogenic (★★) |
| GABRG2 P282S | 282 | Transmembrane | Pathogenic / likely pathogenic (★★) |
| GABRG2 V287I | 287 | Transmembrane | Pathogenic / likely pathogenic (★★) |
| GABRG2 G354V | 354 | Transmembrane | Pathogenic / likely pathogenic (★★) |
| GABRG2 R363Q | 363 | Cytoplasmic | Pathogenic / likely pathogenic (★★) |
| GABRG2 N72K | 72 | Extracellular | Pathogenic / likely pathogenic (★★) |
| GABRB3 D49G | 49 | Extracellular | Pathogenic / likely pathogenic (★) |
| GABRB3 T156I | 156 | Extracellular | Pathogenic / likely pathogenic (★) |
| GABRB3 T156N | 156 | Extracellular | Pathogenic / likely pathogenic (★) |
| GABRB3 P253H | 253 | Transmembrane | Pathogenic / likely pathogenic (★) |
| GABRB3 S254Y | 254 | Transmembrane | Pathogenic / likely pathogenic (★) |
| GABRG2 R82L | 82 | Extracellular | Pathogenic / likely pathogenic (★) |
| GABRG2 R323G | 323 | Extracellular | Pathogenic / likely pathogenic (★) |
| GABRA1 T292I | 292 | Transmembrane | Pathogenic / likely pathogenic (★) |
| GABRG2 T311A | 311 | Transmembrane | Pathogenic / likely pathogenic (★) |
| GABRA1 E277G | 277 | Cytoplasmic | Pathogenic / likely pathogenic (★) |
| GABRB3 T157M | 157 | Extracellular | Pathogenic / likely pathogenic (★) |
| GABRB3 R232P | 232 | Extracellular | Pathogenic / likely pathogenic (★) |
| GABRB3 L256V | 256 | Transmembrane | Pathogenic / likely pathogenic (★) |
| GABRB3 K299Q | 299 | Extracellular | Pathogenic / likely pathogenic (★) |
| GABRB3 I306T | 306 | Transmembrane | Pathogenic / likely pathogenic (★) |
| GABRG2 P83L | 83 | Extracellular | Pathogenic / likely pathogenic (★) |
| GABRG2 A300T | 300 | Cytoplasmic | Pathogenic / likely pathogenic (★) |
| GABRG2 A303T | 303 | Transmembrane | Pathogenic / likely pathogenic (★) |
| GABRG2 S306F | 306 | Transmembrane | Pathogenic / likely pathogenic (★) |
| GABRG2 T314S | 314 | Transmembrane | Pathogenic / likely pathogenic (★) |
| GABRG2 I321T | 321 | Transmembrane | Pathogenic / likely pathogenic (★) |
| GABRG2 R363G | 363 | Cytoplasmic | Pathogenic / likely pathogenic (★) |
| GABRG2 R125H | 125 | Extracellular | Pathogenic / likely pathogenic (★) |
| GABRG2 A334V | 334 | Extracellular | Pathogenic / likely pathogenic (★) |
| GABRA1 F42L | 42 | Extracellular | Pathogenic / likely pathogenic (★) |
| GABRA1 F92S | 92 | Extracellular | Pathogenic / likely pathogenic (★) |
| GABRA1 A188D | 188 | Extracellular | Pathogenic / likely pathogenic (★) |
Showing 60 of 80.
Uncertain variants prioritized for review in EPILEPSY, CHILDHOOD ABSENCE, SUSCEPTIBILITY TO, 2
| Variant | Position | Protein part | Clinical label | Evidence |
|---|---|---|---|---|
| GABRG2 A334T | 334 | Extracellular | Conflicting reports (★) | +7: 2 other pathogenic changes within 3 positions; A334V at the same position is pathogenic; seen in 6.6e-06 of gnomAD DNA copies; REVEL 0.824 |
| GABRG2 T314K | 314 | Transmembrane | Conflicting reports (★) | +6: 2 other pathogenic changes within 3 positions; T314S at the same position is pathogenic; not seen in the gnomAD population database; AlphaMissense 1.00 |
| GABRG2 P83T | 83 | Extracellular | Conflicting reports (★) | +6: 4 other pathogenic changes within 3 positions; P83L at the same position is pathogenic; not seen in the gnomAD population database; AlphaMissense 1.00 |
| GABRB3 T288A | 288 | Transmembrane | Conflicting reports (★) | +6: 2 other pathogenic changes within 3 positions; T288I at the same position is pathogenic; not seen in the gnomAD population database; AlphaMissense 0.97 |
| GABRB3 K127R | 127 | Extracellular | Conflicting reports (★) | +6: 2 other pathogenic changes within 3 positions; K127E at the same position is pathogenic; not seen in the gnomAD population database; AlphaMissense 0.58 |
| GABRA1 R214S | 214 | Extracellular | Conflicting reports (★) | +6: 2 other pathogenic changes within 3 positions; R214C at the same position is pathogenic; not seen in the gnomAD population database; AlphaMissense 0.88 |
| GABRG2 Y331N | 331 | Extracellular | Uncertain (★) | +6: 2 other pathogenic changes within 3 positions; Y331C at the same position is pathogenic; not seen in the gnomAD population database; AlphaMissense 0.95 |
| GABRB3 K304E | 304 | Extracellular | Uncertain (★) | +6: 4 other pathogenic changes within 3 positions; K304R at the same position is pathogenic; not seen in the gnomAD population database; AlphaMissense 1.00 |
| GABRG2 A300D | 300 | Cytoplasmic | Uncertain (★) | +6: 2 other pathogenic changes within 3 positions; A300T at the same position is pathogenic; not seen in the gnomAD population database; AlphaMissense 1.00 |
| GABRA1 N275S | 275 | Cytoplasmic | Uncertain (★★) | +6: 2 other pathogenic changes within 3 positions; N275K at the same position is pathogenic; not seen in the gnomAD population database; AlphaMissense 0.66 |
| GABRB3 D49E | 49 | Extracellular | Uncertain (★★) | +6: 3 other pathogenic changes within 3 positions; D49G at the same position is pathogenic; not seen in the gnomAD population database; AlphaMissense 1.00 |
| GABRA1 E277D | 277 | Cytoplasmic | Uncertain (★) | +6: 3 other pathogenic changes within 3 positions; E277G at the same position is pathogenic; not seen in the gnomAD population database; AlphaMissense 0.97 |
| GABRB3 T185P | 185 | Extracellular | Uncertain (★) | +6: 2 other pathogenic changes within 3 positions; T185I at the same position is pathogenic; not seen in the gnomAD population database; AlphaMissense 0.86 |
Which prediction tools work for EPILEPSY, CHILDHOOD ABSENCE, SUSCEPTIBILITY TO, 2
Observed separation of ClinVar pathogenic / likely pathogenic from benign / likely benign variants (AUROC × 100). This benchmark is not a clinical recommendation.
- AlphaMissense: 94 out of 100
- ESM1b (LLR): 94 out of 100
- PolyPhen-2: 92 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- MutPred: 92 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- CATVariant: 92 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- MetaSVM: 91 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- MetaLR: 90 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- REVEL: 89 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- SIFT: 85 out of 100
- CADD: 81 out of 100
- phyloP: 65 out of 100
- SpliceAI: 55 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- Pangolin: 42 out of 100 (learned from overlapping clinical labels, so this is optimistic)
Same protein, different disease
- Developmental and epileptic encephalopathy also has ClinVar records linked to GABRB3 variants; they fall partly in the same places as the EPILEPSY, CHILDHOOD ABSENCE, SUSCEPTIBILITY TO, 2 variants (22 pathogenic / likely pathogenic).
- Developmental and epileptic encephalopathy also has ClinVar records linked to GABRG2 variants; they fall partly in the same places as the EPILEPSY, CHILDHOOD ABSENCE, SUSCEPTIBILITY TO, 2 variants (8 pathogenic / likely pathogenic).
- Idiopathic generalized epilepsy also has ClinVar records linked to GABRA1 variants; they fall partly in the same places as the EPILEPSY, CHILDHOOD ABSENCE, SUSCEPTIBILITY TO, 2 variants (24 pathogenic / likely pathogenic).
- Developmental and epileptic encephalopathy also has ClinVar records linked to GABRA1 variants; they fall partly in the same places as the EPILEPSY, CHILDHOOD ABSENCE, SUSCEPTIBILITY TO, 2 variants (15 pathogenic / likely pathogenic).
Diseases related to EPILEPSY, CHILDHOOD ABSENCE, SUSCEPTIBILITY TO, 2
- Developmental and epileptic encephalopathy, also linked to GABRA1, GABRB3 and GABRG2
- Epilepsy, also linked to GABRA1, GABRB3 and GABRG2
- Migraine, also linked to GABRA1, GABRB3 and GABRG2
- Lennox-Gastaut syndrome, also linked to GABRA1, GABRB3 and GABRG2
- Generalized epilepsy with febrile seizures plus, also linked to GABRG2
- Idiopathic generalized epilepsy, also linked to GABRA1
- Familial febrile seizures, also linked to GABRG2
- Rolandic epilepsy, also linked to GABRG2
- Autosomal dominant nocturnal frontal lobe epilepsy, also linked to GABRG2
- Genetic developmental and epileptic encephalopathy, also linked to GABRG2
Frequently asked questions
Which genes have records linked to EPILEPSY, CHILDHOOD ABSENCE, SUSCEPTIBILITY TO, 2?
This view contains 3 analyzed proteins: GABRB3, GABRG2, GABRA1. Links come from clinical records and association databases. They do not imply that every listed gene is a validated cause, and missing genes may not yet be analyzed.
What do the clinical classifications mean?
Linked records include 80 pathogenic or likely pathogenic variants, 458 variants of uncertain significance and 74 with conflicting classifications. Labels summarize source records; multi-condition records may not make a separate assertion for this disease. Check the original record and review status.
Does the evidence score change a VUS classification?
No. 13 VUS or conflicting variants reach the likely-pathogenic points range on the computable criteria available here. This is a research prioritization signal, not a clinical classification. Patient, family and other required evidence may be missing.
Can I download the variant evidence?
Download the CSV for all 649 variants in the selected disease scope, including clinical labels, review status, evidence criteria, predictor scores, functional measurements and population frequency where available.
About this data
Variant–disease links come from ClinVar, Open Targets and UniProt, pooled from eligible public CATVariant analyses of each human protein. Evidence scores use the ACMG/AMP Bayesian points scale with computable criteria only (position among known disease variants, rarity in gnomAD, calibrated predictors, deep mutational scanning); there is no family or patient data, so they prioritise variants for expert review and never classify them.
Download every variant as CSV · Browse all diseases · Methods · About the Center